Clinical Trials Info:

Psoriasis/Psoriatic Arthritis Clinical Studies

The role of food sensitivity in psoriasis: a 12-week prospective correlational study of the impact of an individualized elimination diet on disease severity

Enrollment status: Open

Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients’ symptoms. The purpose of this study is to determine whether psoriasis patients are more likely to have food sensitivities than those patients without psoriasis. We will also determine if eliminating certain foods from the diet results in a change in psoriasis symptoms.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 685

A Single Arm Multiple Dose Study to Access the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis

Enrollment status: Open

Generalized Pustular Psoriasis (GPP) is when the body has abnormal immune reactions that cause a potentially serious inflammatory state that results in skin rash and systemic manifestations (e.g., fever, chills).  This study is being done to assess the effects of the experimental study drug (ANB019) in patients with GPP.  The study will assess the effect of study drug on your skin symptoms, plaque psoriasis (if present), the pharmacokinetics (PK) (looking at the amount of drug in your blood to evaluate the way the body processes the drug), systemic manifestations and your general wellbeing. The safety and tolerability of ANB019 will be monitored throughout the study.  The study drug is a protein drug substance that regulates the immune system of the body and may be useful in treating patients with GPP.  The study is being carried out by a company called IQVIA RDS Inc. on behalf of AnaptysBio, Inc.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 734

Human Psoriasis Skin Explant Model

Enrollment status: Open

The purpose of this study is to determine if we can use skin biopsies of psoriatic skin to predict if a person with psoriasis will respond to a treatment or not. Normal healthy skin will be used to determine the behavior of healthy tissue in this system. As well, additional exploratory research may be performed on skin samples remaining after the completion of the main study. There is an optional exploratory sub-study associated with this study for blood and urine samples. Exploratory research can help to improve our understanding of how individuals respond to drugs and our ability to predict, detect, monitor diseases and their progression, as well as lead to the development of new therapies, research methods, or technologies.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 686

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

Enrollment status: Open

The purpose of this study is to measure how safe and effective BMS-986165 is in treating participants with psoriasis. Other research studies in animals and in humans showed that BMS-986165 may help control the immune system that is responsible for the signs and symptoms of psoriasis by controlling the molecules in the body responsible for inflammation within the skin. In addition, blood samples will be collected to assess how the study treatments affect your body and may be used to better understand psoriasis, associated medical conditions, or who may respond to the study treatments. These biomarker samples will be used to measure things like: proteins, fats, RNA and DNA. Sometimes it is not known which way of treating people is best. To find out, researchers need to compare different treatments in research studies. The study will have three groups of participants who will receive either BMS-986165, placebo or apremilast; as a result, you may receive a placebo, which contains no active ingredient; you may receive apremilast which is approved for treatment of moderate-to-severe plaque psoriasis or you may receive BMS-986165. The group you are in will be selected at random. You will have a 1 in 2 chance of receiving the BMS-986165, a 1 in 4 chance of receiving apremilast and a 1 in 4 chance of receiving placebo.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 728

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Enrollment status: Open

The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients’ symptoms. Amongst patients with skin disease, there is significant interest in using complementary alternative medicine and vitamins to treat their disease. Previous human case reports suggest that riboflavin, commonly known as Vitamin B2, is clinically effective for the treatment of psoriasis; however, they were not conclusive. More recent human trials have shown that 400 mg of daily oral riboflavin is a safe and well-tolerated medication to administer to humans. Our laboratory data, the published case reports of riboflavin’s effectiveness and its safety led us to propose these clinical and laboratory experiments to better determine riboflavin’s effects on psoriasis. For the purpose of this study, the riboflavin is used as an investigational drug.

Study coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 677

Personalized Medicine through Integration of Immune Phenotypes in Autoimmune Skin Disease

Enrollment status: Contact us for status

We aim to expand our ability to pick the right treatments for patients with diseases such as lupus and psoriasis. To do this, we need to develop a better understanding of how these diseases behave and respond to treatments over time. Through the Taubman Medical Research Institute, we have been granted funds to follow a cohort of patients to better understand the specific skin and immune system abnormalities that cause diseases like lupus or psoriasis. Our study is Personalized Medicine through Integration of Immune Phenotypes in Autoimmune Skin Diseases. We would like you to consider joining our cohort. This will mean that you will have a research visit after most of your regularly scheduled clinic visits during which we will collect information such as pain and fatigue levels, medication changes, and disease activity. We will also ask for a blood sample at every visit and occasionally a skin biopsy to study the skin responses (but not at every visit). We will use this information to map out your immune responses and how the medications change them in relation to your clinical improvement. You will be compensated for your time for each research visit.

Study coordinator: Rewaa Yas, (734) 936-3889 or rewaay@med.umich.edu
Please reference Tiip study

Familial Psoriasis Study

The University of Michigan Psoriasis Genetics Research Program is studying psoriasis (a common inflammatory skin disease) and psoriatic arthritis (a related degenerative musculoskeletal condition).

These conditions are influenced by both genetic and environmental factors, with up to 30% of those affected by psoriasis eventually also developing psoriatic arthritis. For our research, we are seeking genetic material from:

  • those with psoriasis and/or psoriasis arthritis
  • those who are unrelated and unaffected by psoriasis and/or psoriasis arthritis. 

We are also collecting samples from large families affected by psoriasis and/or psoriatic arthritis (those with five or more family members affected.)  For more information about the U-M Psoriasis Genetics Research Program contact us at: psoriasis@umich.edu or call 1-800-356-2840 (weekdays, 9am-4pm, Eastern time zone).